William Garrett Nichols - 28 Jul 2025 Form 4 Insider Report for Candel Therapeutics, Inc. (CADL)

Reporting relationship: Chief Medical Officer
Issuer ticker: CADL
Reported as of: 28 Jul 2025
Net transaction value: -$5,332
SEC form: 4
Accepted by SEC: 30 Jul 2025, 16:30:16 UTC
Prior SEC filing: 02 Jul 2025
Next SEC filing: 28 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Charles Schoch, as Attorney-In-Fact for William Garrett Nichols

Key filing fact

William Garrett Nichols filed Form 4 for Candel Therapeutics, Inc. (CADL) on 30 Jul 2025.

Key facts

This page summarizes William Garrett Nichols's Form 4 filing for Candel Therapeutics, Inc. (CADL).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 30 Jul 2025, 16:30.

Change

Previous filing in this sequence was filed on 02 Jul 2025.
Current net transaction value: -$5,332.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001618364 Primary reporting owner

Nichols William Garrett

Relationship: Chief Medical Officer
Address: C/O CANDEL THERAPEUTICS, INC., 117 KENDRICK ST., SUITE 450, NEEDHAM
Signature: /s/ Charles Schoch, as Attorney-In-Fact for William Garrett Nichols
Signature date: 30 Jul 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CADL transaction

Common Stock

Options Exercise

Transaction value: $1,209
Shares: +937
Change %: +1.8%
Price: $1.29
Shares after: 53,430
Date: 28 Jul 2025
Ownership: Direct
Footnotes: F1

CADL transaction

Common Stock

Sale

Transaction value: $6,540
Shares: -937
Change %: -1.8%
Price: $6.98
Shares after: 52,493
Date: 28 Jul 2025
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CADL transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value: $0
Shares: -937
Change %: -3.1%
Price: $0.000000
Shares after: 29,377
Date: 28 Jul 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 937
Exercise price: $1.29
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 2 footnotes

Footnote F1

This transaction reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on 11/22/2024.

Footnote F2

This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following April 28, 2023, subject to the Reporting Person's continued service on each vesting date.